{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:20:17Z","timestamp":1787818817328,"version":"build-2784847793"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2025 Scientific and Technological Innovation Project for Graduate Students of China Academy of Chinese Medical Sciences","award":["KC2025005"],"award-info":[{"award-number":["KC2025005"]}]},{"name":"Academic Inheritance and Communication Project of China Academy of Chinese Medical Sciences","award":["CI2022E012XB"],"award-info":[{"award-number":["CI2022E012XB"]}]},{"name":"Clinical Research Fund of Central High-level Hospital of Traditional Chinese Medicine: Hospital Preparation Project Based on the Experience of Renowned Traditional Chinese Medicine Practitioners","award":["HLCMHPP2023053"],"award-info":[{"award-number":["HLCMHPP2023053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07941-z","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:04:02Z","timestamp":1787817842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal"],"prefix":"10.1007","author":[{"given":"Zhaoqi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"16","key":"7941_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/nejmoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"7941_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/nejmoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/nejmoa2206286.","journal-title":"N Engl J Med"},{"issue":"16","key":"7941_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/nejmoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/nejmoa2407107.","journal-title":"N Engl J Med"},{"issue":"12","key":"7941_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/nejmoa2306963.","journal-title":"N Engl J Med"},{"issue":"5","key":"7941_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/nejmoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/nejmoa2410027.","journal-title":"N Engl J Med"},{"issue":"4","key":"7941_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7941_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","volume":"4","author":"C Franssen","year":"2016","unstructured":"Franssen C, Chen S, Unger A, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4(4):312\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2015.10.007.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"7941_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/circulationaha.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6\u201319. https:\/\/doi.org\/10.1161\/circulationaha.116.026807.","journal-title":"Circulation"},{"issue":"8","key":"7941_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(8):657\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.016.","journal-title":"JACC Heart Fail"},{"issue":"16","key":"7941_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/eurheartj\/ehaa823","volume":"42","author":"H Sorimachi","year":"2021","unstructured":"Sorimachi H, Obokata M, Takahashi N, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(16):1595\u2013605. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa823.","journal-title":"Eur Heart J"},{"issue":"3","key":"7941_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/circulationaha.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269\u201379. https:\/\/doi.org\/10.1161\/circulationaha.114.010637.","journal-title":"Circulation"},{"issue":"8","key":"7941_CR12","doi-asserted-by":"publisher","first-page":"e006414","DOI":"10.1161\/circheartfailure.119.006414","volume":"13","author":"MS Sabbah","year":"2020","unstructured":"Sabbah MS, Fayyaz AU, de Denus S, et al. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2020;13(8):e006414. https:\/\/doi.org\/10.1161\/circheartfailure.119.006414.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"7941_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/nejmoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/nejmoa1707914.","journal-title":"N Engl J Med"},{"issue":"12","key":"7941_CR14","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/ejhf.2616","volume":"24","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Aimo A, Merlo M, et al. Value of the HFA-PEFF and H(2) FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. Eur J Heart Fail. 2022;24(12):2374\u201386. https:\/\/doi.org\/10.1002\/ejhf.2616.","journal-title":"Eur J Heart Fail"},{"issue":"40","key":"7941_CR15","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297\u2013317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641.","journal-title":"Eur Heart J"},{"issue":"9","key":"7941_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/circulationaha.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BAA, Simple. Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861\u201370. https:\/\/doi.org\/10.1161\/circulationaha.118.034646.","journal-title":"Circulation"},{"issue":"35","key":"7941_CR17","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.jaccas.2025.105594","volume":"30","author":"MG Bellicini","year":"2025","unstructured":"Bellicini MG. HFpEF Diagnosis: A Controversial Construct in Modern Cardiology. JACC Case Rep. 2025;30(35):105594. https:\/\/doi.org\/10.1016\/j.jaccas.2025.105594.","journal-title":"JACC Case Rep"},{"issue":"21","key":"7941_CR18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/circulationaha.120.045810","volume":"142","author":"S Sanders-van Wijk","year":"2020","unstructured":"Sanders-van Wijk S, Tromp J, Beussink-Nelson L, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation. 2020;142(21):2029\u201344. https:\/\/doi.org\/10.1161\/circulationaha.120.045810.","journal-title":"Circulation"},{"issue":"11","key":"7941_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267\u201374. https:\/\/doi.org\/10.1001\/jamacardio.2021.3070.","journal-title":"JAMA Cardiol"},{"key":"7941_CR20","doi-asserted-by":"publisher","unstructured":"Aimo A, Castiglione V, Panichella G, et al. Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis. ESC Heart Fail. 2026;xvag172. https:\/\/doi.org\/10.1093\/eschf\/xvag172.","DOI":"10.1093\/eschf\/xvag172"},{"issue":"16","key":"7941_CR21","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"issue":"11","key":"7941_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"7941_CR23","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehy531.","journal-title":"Eur Heart J"},{"issue":"20","key":"7941_CR24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","volume":"43","author":"FH Verbrugge","year":"2022","unstructured":"Verbrugge FH, Omote K, Reddy YNV, Sorimachi H, Obokata M, Borlaug BA. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J. 2022;43(20):1941\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehab911.","journal-title":"Eur Heart J"},{"issue":"4","key":"7941_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12471-016-0816-8","volume":"24","author":"WC Meijers","year":"2016","unstructured":"Meijers WC, Hoekstra T, Jaarsma T, van Veldhuisen DJ, de Boer RA. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24(4):287\u201395. https:\/\/doi.org\/10.1007\/s12471-016-0816-8.","journal-title":"Neth Heart J"},{"key":"7941_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-026-05836-3","author":"C Chen","year":"2026","unstructured":"Chen C, Zhang S, Liu Y, et al. Inflammatory-lipid residual risk phenotypes delineate the HFpEF probability spectrum independent of cardiometabolic mediation. BMC Cardiovasc Disord. 2026. https:\/\/doi.org\/10.1186\/s12872-026-05836-3.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"7941_CR27","doi-asserted-by":"publisher","first-page":"Article16","DOI":"10.37616\/2212-5043.1501","volume":"38","author":"A Albulushi","year":"2026","unstructured":"Albulushi A, Tawfek A, Basuoni A. CT-Derived Epicardial Adipose Tissue Density and Its Association With Systemic Inflammation and Functional Impairment in Heart Failure With Preserved Ejection Fraction: A Prospective Cross-Sectional Study From Oman. J Saudi Heart Assoc. 2026;38(2):Article16. https:\/\/doi.org\/10.37616\/2212-5043.1501.","journal-title":"J Saudi Heart Assoc"},{"issue":"9","key":"7941_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020;8(9):712\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"7941_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1084\/jem.20171274","volume":"215","author":"M Hulsmans","year":"2018","unstructured":"Hulsmans M, Sager HB, Roh JD, et al. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018;215(2):423\u201340. https:\/\/doi.org\/10.1084\/jem.20171274.","journal-title":"J Exp Med"},{"issue":"4","key":"7941_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/ehf2.12700","volume":"7","author":"C Hage","year":"2020","unstructured":"Hage C, Michaelsson E, Kull B, et al. Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. ESC Heart Fail. 2020;7(4):1534\u201346. https:\/\/doi.org\/10.1002\/ehf2.12700.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"7941_CR31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.cjca.2024.03.018","volume":"40","author":"BL Dumont","year":"2024","unstructured":"Dumont BL, Neagoe PE, Charles E, et al. Low-Density Neutrophils and Neutrophil Extracellular Traps (NETs) Are New Inflammatory Players in Heart Failure. Can J Cardiol. 2024;40(9):1524\u201335. https:\/\/doi.org\/10.1016\/j.cjca.2024.03.018.","journal-title":"Can J Cardiol"},{"issue":"3","key":"7941_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1083\/jcb.201006052","volume":"191","author":"V Papayannopoulos","year":"2010","unstructured":"Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191(3):677\u201391. https:\/\/doi.org\/10.1083\/jcb.201006052.","journal-title":"J Cell Biol"},{"issue":"23\u201324","key":"7941_CR33","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.cca.2010.08.013","volume":"411","author":"N Li","year":"2010","unstructured":"Li N, Bian H, Zhang J, Li X, Ji X, Zhang Y. The Th17\/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin Chim Acta. 2010;411(23\u201324):1963\u20138. https:\/\/doi.org\/10.1016\/j.cca.2010.08.013.","journal-title":"Clin Chim Acta"},{"key":"7941_CR34","doi-asserted-by":"publisher","unstructured":"Smolgovsky S, Bayer AL, Kaur K, et al. Impaired T cell IRE1alpha\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction. J Clin Invest. 2023;133(24). https:\/\/doi.org\/10.1172\/JCI171874.","DOI":"10.1172\/JCI171874"},{"issue":"1","key":"7941_CR35","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/circheartfailure.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13(1):e006277. https:\/\/doi.org\/10.1161\/circheartfailure.119.006277.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"7941_CR36","doi-asserted-by":"publisher","first-page":"e005036","DOI":"10.1161\/circheartfailure.118.005036","volume":"11","author":"BW Van Tassell","year":"2018","unstructured":"Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018;11(8):e005036. https:\/\/doi.org\/10.1161\/circheartfailure.118.005036.","journal-title":"Circ Heart Fail"},{"issue":"22","key":"7941_CR37","doi-asserted-by":"publisher","first-page":"e019390","DOI":"10.1161\/jaha.120.019390","volume":"9","author":"RB Patel","year":"2020","unstructured":"Patel RB, Colangelo LA, Bielinski SJ, et al. Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2020;9(22):e019390. https:\/\/doi.org\/10.1161\/jaha.120.019390.","journal-title":"J Am Heart Assoc"},{"issue":"7752","key":"7941_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1100-z.","journal-title":"Nature"},{"issue":"6","key":"7941_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/circulationaha.114.009625","volume":"131","author":"SF Mohammed","year":"2015","unstructured":"Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550\u20139. https:\/\/doi.org\/10.1161\/circulationaha.114.009625.","journal-title":"Circulation"},{"issue":"10","key":"7941_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W, et al. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol. 2018;72(10):1081\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.050.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7941_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","volume":"53","author":"K Damman","year":"2009","unstructured":"Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2008.08.080.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7941_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cardfail.2020.01.003","volume":"26","author":"RB Patel","year":"2020","unstructured":"Patel RB, Mehta R, Redfield MM, et al. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. J Card Fail. 2020;26(3):233\u201342. https:\/\/doi.org\/10.1016\/j.cardfail.2020.01.003.","journal-title":"J Card Fail"},{"issue":"6","key":"7941_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","volume":"8","author":"L Scandalis","year":"2023","unstructured":"Scandalis L, Kitzman DW, Nicklas BJ, et al. Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2023;8(6):575\u201384. https:\/\/doi.org\/10.1001\/jamacardio.2023.0957.","journal-title":"JAMA Cardiol"},{"issue":"13","key":"7941_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.020654","volume":"10","author":"AL Beale","year":"2021","unstructured":"Beale AL, O\u2019Donnell JA, Nakai ME, et al. The gut microbiome of heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10(13):e020654. https:\/\/doi.org\/10.1161\/jaha.120.020654.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"7941_CR45","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ehf2.13290","volume":"8","author":"Y Kinugasa","year":"2021","unstructured":"Kinugasa Y, Nakamura K, Kamitani H, et al. Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction. ESC Heart Fail. 2021;8(3):2103\u201310. https:\/\/doi.org\/10.1002\/ehf2.13290.","journal-title":"ESC Heart Fail"},{"key":"7941_CR46","doi-asserted-by":"publisher","first-page":"131818","DOI":"10.1016\/j.ijcard.2024.131818","volume":"402","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Claggett BL, Liu J, et al. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT. Int J Cardiol. 2024;402:131818. https:\/\/doi.org\/10.1016\/j.ijcard.2024.131818.","journal-title":"Int J Cardiol"},{"issue":"11","key":"7941_CR47","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","volume":"11","author":"A Alogna","year":"2023","unstructured":"Alogna A, Koepp KE, Sabbah M, et al. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2023;11(11):1549\u201361. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.031.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"7941_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ehf2.13174","volume":"8","author":"TD Trippel","year":"2021","unstructured":"Trippel TD, Mende M, Dungen HD, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Fail. 2021;8(2):829\u201341. https:\/\/doi.org\/10.1002\/ehf2.13174.","journal-title":"ESC Heart Fail"},{"key":"7941_CR49","doi-asserted-by":"publisher","unstructured":"Sakamoto D, Matsuoka Y, Nakatani D, et al. Role and prognostic value of growth differentiation factor 15 in patient of heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF registry. Open Heart. 2025;12(1). https:\/\/doi.org\/10.1136\/openhrt-2024-003008.","DOI":"10.1136\/openhrt-2024-003008"},{"issue":"15","key":"7941_CR50","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2016.02.018","volume":"67","author":"KP Rommel","year":"2016","unstructured":"Rommel KP, von Roeder M, Latuscynski K, et al. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2016;67(15):1815\u201325. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.018.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7941_CR51","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/ehf2.13071","volume":"7","author":"T Harada","year":"2020","unstructured":"Harada T, Sunaga H, Sorimachi H, et al. Pathophysiological role of fatty acid-binding protein 4 in Asian patients with heart failure and preserved ejection fraction. ESC Heart Fail. 2020;7(6):4256\u201366. https:\/\/doi.org\/10.1002\/ehf2.13071.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"7941_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201836","volume":"13","author":"HM DuBrock","year":"2018","unstructured":"DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS One. 2018;13(8):e0201836. https:\/\/doi.org\/10.1371\/journal.pone.0201836.","journal-title":"PLoS One"},{"issue":"5","key":"7941_CR53","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ehf2.12621","volume":"7","author":"AB Mendez Fernandez","year":"2020","unstructured":"Mendez Fernandez AB, Ferrero-Gregori A, Garcia-Osuna A, et al. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction. ESC Heart Fail. 2020;7(5):2223\u20139. https:\/\/doi.org\/10.1002\/ehf2.12621.","journal-title":"ESC Heart Fail"},{"key":"7941_CR54","doi-asserted-by":"publisher","first-page":"937291","DOI":"10.3389\/fcvm.2022.937291","volume":"9","author":"Y Shi","year":"2022","unstructured":"Shi Y, Liu J, Liu C, et al. Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:937291. https:\/\/doi.org\/10.3389\/fcvm.2022.937291.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"7941_CR55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41588-024-02064-3","volume":"57","author":"A Henry","year":"2025","unstructured":"Henry A, Mo X, Finan C, et al. Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes. Nat Genet. 2025;57(4):815\u201328. https:\/\/doi.org\/10.1038\/s41588-024-02064-3.","journal-title":"Nat Genet"},{"issue":"13","key":"7941_CR56","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/eurjpc\/zwad209","volume":"30","author":"Y Han","year":"2023","unstructured":"Han Y, Lu J, Chen B, et al. A novel polygenic risk score improves prognostic prediction of heart failure with preserved ejection fraction in the Chinese Han population. Eur J Prev Cardiol. 2023;30(13):1382\u201390. https:\/\/doi.org\/10.1093\/eurjpc\/zwad209.","journal-title":"Eur J Prev Cardiol"},{"issue":"7982","key":"7941_CR57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622(7982):329\u201338. https:\/\/doi.org\/10.1038\/s41586-023-06592-6.","journal-title":"Nature"},{"issue":"12","key":"7941_CR58","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712\u201321. https:\/\/doi.org\/10.1038\/s41588-021-00978-w.","journal-title":"Nat Genet"},{"issue":"5","key":"7941_CR59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41562-019-0566-x","volume":"3","author":"AD Grotzinger","year":"2019","unstructured":"Grotzinger AD, Rhemtulla M, de Vlaming R, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat Hum Behav. 2019;3(5):513\u201325. https:\/\/doi.org\/10.1038\/s41562-019-0566-x.","journal-title":"Nat Hum Behav"},{"issue":"8","key":"7941_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2026.103057","volume":"14","author":"P Zangas","year":"2026","unstructured":"Zangas P, Schuermans A, Georgakis MK. Genetically proxied interleukin-6 signaling inhibition and heart failure risk. JACC Heart Fail. 2026;103057. https:\/\/doi.org\/10.1016\/j.jchf.2026.103057.","journal-title":"JACC Heart Fail"},{"issue":"9822","key":"7941_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"DI Swerdlow","year":"2012","unstructured":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379(9822):1214\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(12)60110-X.","journal-title":"Lancet"},{"key":"7941_CR62","doi-asserted-by":"publisher","first-page":"d548","DOI":"10.1136\/bmj.d548","volume":"342","author":"F Wensley","year":"2011","unstructured":"C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. https:\/\/doi.org\/10.1136\/bmj.d548.","journal-title":"BMJ"},{"issue":"1","key":"7941_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12933-025-02738-0","volume":"24","author":"M Lin","year":"2025","unstructured":"Lin M, Guo J, Tao H, et al. Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis. Cardiovasc Diabetol. 2025;24(1):201. https:\/\/doi.org\/10.1186\/s12933-025-02738-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7941_CR64","doi-asserted-by":"publisher","first-page":"e005031","DOI":"10.1161\/CIRCGEN.124.005031","volume":"19","author":"JN Njoroge","year":"2026","unstructured":"Njoroge JN, van Sanders S, Austin TR, et al. Large-scale proteomic profiling of incident heart failure and its subtypes in older adults. Circ Genom Precis Med. 2026;19(1):e005031. https:\/\/doi.org\/10.1161\/CIRCGEN.124.005031.","journal-title":"Circ Genom Precis Med"},{"issue":"18","key":"7941_CR65","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.393.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7941_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;315(1):36\u201346. https:\/\/doi.org\/10.1001\/jama.2015.17346.","journal-title":"JAMA"},{"issue":"18","key":"7941_CR67","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"issue":"1","key":"7941_CR68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10557-025-07670-9","volume":"40","author":"X Zhang","year":"2026","unstructured":"Zhang X, Cao C, Zheng F, et al. Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. Cardiovasc Drugs Ther. 2026;40(1):287\u2013301. https:\/\/doi.org\/10.1007\/s10557-025-07670-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"7941_CR69","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s10557-025-07822-x","volume":"40","author":"E Habib","year":"2026","unstructured":"Habib E, Ibrahim R, Pham HN, et al. Finerenone versus spironolactone for heart failure with preserved ejection fraction. Cardiovasc Drugs Ther. 2026;40(4):1419\u201322. https:\/\/doi.org\/10.1007\/s10557-025-07822-x.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7941_CR70","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10557-025-07723-z","volume":"40","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2026","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Kindberg KM, Santos-Gallego CG, et al. Sotagliflozin: Two Birds with One Stone? Cardiovasc Drugs Ther. 2026;40(2):671\u20139. https:\/\/doi.org\/10.1007\/s10557-025-07723-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"7941_CR71","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360. https:\/\/doi.org\/10.1038\/s41591-021-01536-x.","journal-title":"Nat Med"},{"issue":"15","key":"7941_CR72","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"9","key":"7941_CR73","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358\u201365. https:\/\/doi.org\/10.1038\/s41591-023-02526-x.","journal-title":"Nat Med"},{"issue":"17","key":"7941_CR74","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Petrie MC, Borlaug BA, et al. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024;84(17):1646\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.028.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7941_CR75","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","volume":"113","author":"BW Van Tassell","year":"2014","unstructured":"Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113(2):321\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2013.08.047.","journal-title":"Am J Cardiol"},{"key":"7941_CR76","doi-asserted-by":"publisher","unstructured":"Mendieta G, Ridker PM, Borlaug BA, et al. Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials. Eur J Heart Fail. 2026:xuag153. https:\/\/doi.org\/10.1093\/ejhf\/xuag153.","DOI":"10.1093\/ejhf\/xuag153"},{"issue":"7","key":"7941_CR77","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jchf.2023.03.002","volume":"11","author":"E Michaelsson","year":"2023","unstructured":"Michaelsson E, Lund LH, Hage C, et al. Myeloperoxidase inhibition reverses biomarker profiles associated with clinical outcomes in HFpEF. JACC Heart Fail. 2023;11(7):775\u201387. https:\/\/doi.org\/10.1016\/j.jchf.2023.03.002.","journal-title":"JACC Heart Fail"},{"issue":"17","key":"7941_CR78","doi-asserted-by":"publisher","first-page":"11485","DOI":"10.1021\/acs.jmedchem.1c02141","volume":"65","author":"T Inghardt","year":"2022","unstructured":"Inghardt T, Antonsson T, Ericsson C, et al. Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022;65(17):11485\u201396. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02141.","journal-title":"J Med Chem"},{"issue":"1","key":"7941_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cardfail.2023.04.003","volume":"30","author":"CSP Lam","year":"2024","unstructured":"Lam CSP, Lund LH, Shah SJ, et al. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results. J Card Fail. 2024;30(1):104\u201310. https:\/\/doi.org\/10.1016\/j.cardfail.2023.04.003.","journal-title":"J Card Fail"},{"issue":"4","key":"7941_CR80","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10741-025-10498-y","volume":"30","author":"V Kittipibul","year":"2025","unstructured":"Kittipibul V, Ambrosy AP, Greene SJ. Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial. Heart Fail Rev. 2025;30(4):735\u20138. https:\/\/doi.org\/10.1007\/s10741-025-10498-y.","journal-title":"Heart Fail Rev"},{"key":"7941_CR81","unstructured":"ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction\u2009>\u200940% (ENDEAVOR). ClinicalTrials.gov identifier: NCT04986202. Updated 27 Aug 2025. Accessed 14 Aug 2026. https:\/\/clinicaltrials.gov\/study\/NCT04986202"},{"issue":"12","key":"7941_CR82","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268\u201377. https:\/\/doi.org\/10.1001\/jama.2013.2024.","journal-title":"JAMA"},{"issue":"24","key":"7941_CR83","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1056\/nejmoa1510774","volume":"373","author":"MM Redfield","year":"2015","unstructured":"Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015;373(24):2314\u201324. https:\/\/doi.org\/10.1056\/nejmoa1510774.","journal-title":"N Engl J Med"},{"issue":"16","key":"7941_CR84","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614\u201321. https:\/\/doi.org\/10.1001\/jama.2021.18236.","journal-title":"JAMA"},{"issue":"9596","key":"7941_CR85","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07941-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:04:05Z","timestamp":1787817845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07941-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":85,"alternative-id":["7941"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07941-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"21 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This narrative review did not involve new research with human participants or animals.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}